Defining the ideal human Amniotic progenitor Secretome forMulation for future cArdioprotective paRacrine Therapy

Acronym : AmnioSMART

Call : CardInnov 2023

logo

Topic

Novel therapeutic strategies to boost cardiac repair and prevent the onset of heart failure currently represent an unmet clinical need. The cardiovascular patient requires timely intervention to tackle specific pathological processes within the injured or diseased heart; therefore, ready-to-use formulations should be easily accessible as off-the-shelf medicinal products for prompt administration and in compliance with the patient s needs.

The AmnioSMART project will optimize a new approach based on soluble derivatives from human progenitor cells with promising potential to provide effective anti-inflammatory and cardioprotective therapeutic effects. Our team has previously identified in human mesenchymal stromal cells from term placenta and from amniotic fluid an appealing asset to derive cell-free soluble formulations with regenerative potential. These cells can be easily obtained from biological waste material at birth and from leftover samples of prenatal diagnosis donated to research from informed donors, thus offering a feasible resource for future regenerative medicine applications.

This project will also develop an innovative, yet feasible strategy based on biomaterial formulations to ensure controlled, targeted and sustained administration to the heart of the therapeutic solution with the highest potential for the treatment of cardiovascular disease and for patient compliance.

The transnational team of AmnioSMART research will employ advanced cellular and molecular technology to provide an integrative approach with clear transition from basic research into clinical application. 

  • Coordinator:

    Sveva BOLLINI, IRCCS Ospedale Policlinico San Martino, Genova, Italy

  • Partners:
    • Monika GLADKA, Amsterdam University Medical Centers Amsterdam, The Netherlands
    • Rui L. REIS, University of Minho Braga, Portugal
    • Ornella PAROLINI, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome, Italy
    • Maurilio SAMPAOLESI, KU Leuven Leuven, Belgium
Back to index